SIGMA Pharmaceuticals is
hoping to stave off investor
movements after it confirmed that
Aspen Pharmaceuticals is yet to
place a formal take-over offer.
In a statement this morning
Sigma continued to urge investorsto
“take no action at this time.
“Sigma is continuing the
previously foreshadowed asset sale
program and will consider other
opportunities that may enable it to
improve shareholder value,” it said.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.